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INTRODUCTION: The rarity of dedifferentiated liposarcoma (DDLPS) and the lack of experimental DDLPS models limit the
developmentof novel therapeutic strategies. Pazopanib (PAZ) is a tyrosine kinase inhibitor that is approved for the treatmentof
non-adipocytic advanced soft tissue sarcoma. The activity of this agent has not yet been properly explored in preclinical
liposarcoma models nor in a randomized phaseШ clinical trial in this entity. The aim of the present study was to investigate
whetherPAZhadantitumoractivity inDDLPSmodels in vivo.MATERIALANDMETHODS:Weestablished twopatient-derived
DDLPS xenograft models (UZLX-STS3 and UZLX-STS5) through implantation of tumor material from sarcoma patients in
athymic nude NMRImice. An animal model of the SW872 liposarcoma cell line was also used. To investigate the efficacy of
PAZ in vivo, mice bearing tumors were treated for 2 weeks with sterile water, doxorubicin (1.2mg/kg, intraperitoneally, twice
per week), PAZ [40 mg/kg, orally (p.o.), twice per day], or PAZ plus doxorubicin (same schedules as for single treatments).
RESULTS:Patient-derivedxenografts retained thehistologicandmolecular featuresofDDLPS.PAZsignificantlydelayed tumor
growth by decreasing proliferation and inhibited angiogenesis in all models tested. Combining the angiogenesis
inhibitor with an anthracycline did not show superior efficacy.CONCLUSION: These results suggest that PAZ has potential
antitumor activity in DDLPS primarily through antiangiogenic effects and therefore should be explored in clinical trials.
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Liposarcomas arise from adipose tissue, representing the most frequent
group of adult soft tissue sarcoma (STS). Liposarcomas are classified
into four subtypes: atypical lipomatous tumor (ALT), dedifferentiated
liposarcoma (DDLPS), myxoid liposarcoma, and pleomorphic lipo-
sarcoma. ALT and DDLPS, which are the most common subtypes, are
cytogenetically characterized by chromosome 12q amplification leading
to mouse double minute 2 homolog (MDM2) and/or cyclin-dependent
kinase 4 gene amplification [1–3]. Surgical resection is the primary
potentially curative treatment for localized liposarcomas, while patients
with local advanced or metastatic disease qualify for palliative systemic
therapy. Doxorubicin is the most commonly used first-line treatment
for advanced liposarcomas but has only limited efficacy [3,4].
Limitations for the development of innovative and effective treatments
are the low incidence of liposarcomas, the heterogeneous clinical course
of this disease, and the lack of experimental models.
Angiogenesis plays a fundamental role in the progression of cancers
and is mainly activated by the vascular endothelial growth factor
receptor (VEGFR) and the platelet-derived growth factor receptor
(PDGFR) signaling pathways [5,6]. Overexpression of VEGF and
VEGFR is frequently found in patients bearing primary STS [6–8].
Serum VEGF levels in patients with different types of primary STS,
including liposarcoma, are higher than those in healthy individuals [9].
Pazopanib (PAZ) is a small molecule multitargeted tyrosine kinase
inhibitor, which mainly inhibits VEGFR, PDGFR, and KIT [10].
PAZ is approved for treatment of patients with renal cell carcinoma
and for non-adipocytic advanced STS [11–13]. The liposarcoma
stratum of a multi-sarcoma phase II study was closed early because it
did not reach the predefined level of an antitumor efficacy [14].
However, after central pathologic review, two tumors registered for
this trial as non-adipocytic STS were reclassified as liposarcoma, and
these patients did benefit from PAZ treatment by achieving disease
stabilization at 12 weeks of treatment [11,14]. In retrospect, PAZ
thus did show some clinical activity in adipocytic tumors, warranting
further clinical exploration. At present, two phase II trials, testing
PAZ in patients with liposarcoma, are revisiting this issue
(ClinicalTrials.gov identifier: NCT01692496 and NCT01506596).
In our present preclinical study, we describe the development of
two patient-derived DDLPS xenograft models and the exploration of
the in vivo activity of PAZ in DDLPS, using these models. Our study
provides additional support for the ongoing clinical trials testing PAZ
in patients with advanced DDLPS.Material and Methods
Drugs and Reagents
Doxorubicin hydrochloride (DOX; Sigma-Aldrich, St. Louis,
Missouri) was dissolved in sterile 0.9% NaCl. PAZ (Sequoia Research
Products, Pangbourne, United Kingdom) was dissolved in 0.5%
hydroxypropyl methylcellulose (Sigma-Aldrich) with 1% Tween 80
(Sigma-Aldrich), pH 1.3 to 1.5. Before the administration, the solution
was sonicated for at least 5 minutes. The following antibodies were used
for Western blot analysis: VEGFR2 (55B11), phospho-VEGFR2
(15D2), AKT, phospho-AKT Ser473, p42/p44 mitogen-activated
protein kinases (MAPK), phospho-T202/T204 MAPK, eukaryotic
translation initiation factor 4E-binding protein 1, phospho–4E-binding
protein 1, S6, phospho-S6, α-tubulin (all rabbit, 1:1000 dilution; Cell
Signaling Technology, Danvers, Massachusetts). The secondary anti-
rabbit antibody (1:2000 dilution) was purchased from DAKO(Glostrup, Denmark). Western blot analysis was performed using
NuPAGE Bis-Tris gels (4-12%; Life Technologies, Carlsbad,
California). For immunohistochemical (IHC) staining, antibodies
against phospho-histone H3 (pHH3), cleaved caspase-3 (CC3), and
VEGFR2were purchased fromCell Signaling Technology. In addition,
antibodies against Ki67 (Thermo Scientific, Rockford, Illinois), CD34
(Abcam, Cambridge, United Kingdom), and MDM2 (Life Technol-
ogies) were used. HRP polyclonal goat anti-rabbit Igs, anti-rabbit
EnVision+ System–HRP-labeled polymer, and 3′-diaminobenzidine-
tetrahydrochloride were purchased from DAKO. For VEGFR2
immunostaining, SignalStain, the Boost IHC Detection Reagent
(HRP, rabbit; Cell Signaling Technology), was used.
Establishment of Mouse DDLPS Xenografts
Female adult, partially immunodeficient, athymic NMRI nu/nu
mice (JANVIER LABS, Saint Berthevin, France) were used for
establishing xenograft models and for the in vivo experiments.
Collection and usage of tumor samples from consenting patients were
approved by theMedical Ethics Committee, University Hospitals Leuven.
Animal experiments were approved by the Ethics Committee for
Laboratory Animals, KU Leuven (Leuven, Belgium).
The SW872 liposarcoma cell line (Cell Lines Service, Eppelheim,
Germany) was cultured in Dulbecco's modified Eagle's medium/
F12 medium with 10% FBS (all from Life Technologies). The
SW872 cell line has been previously studied in vitro and in vivo
[15,16]. The SW872 model was generated by subcutaneous,
bilateral injection of 5 × 106 cells per mouse site. Patient-derived
DDLPS xenografts (UZLX-STS3 and UZLX-STS5) were estab-
lished by bilateral subcutaneous implantation of fresh surgically
resected tumor specimens from patients with DDLPS. Tumor tissue
was further re-transplanted from mouse to mouse at least twice.
From each passage, tumor fragments were collected for histologic
and molecular characterization.
Molecular Characterization of Xenografted Tumors
To assessMDM2 copy number, a dual-color interphase fluorescence
in situ hybridization (FISH) using the LSI MDM2/CEP 12 FISH
Probe Kit (Abbott Molecular, North Chicago, Illinois) was performed
on paraffin sections. Hybridization and detection were carried out as
previously described [17]. In addition, the copy number ofMDM2 and
cyclin-dependent kinase 4 was evaluated using quantitative polymerase
chain reaction (qPCR), using HsRBP4 as a control gene (all primer
sequences available on request). DNA was isolated from frozen
tumor fragments, using QIAamp DNA Mini Kit (Qiagen, Venlo,
Netherlands). qPCR analysis was performed using Light Cycler 480
(Roche Diagnostics, Basel, Switzerland).
In Vivo Experiments
For the in vivo studies, we used 18 mice with SW872, 18 with
UZLX-STS3 (p.7), and 18 with UZLX-STS5 (p.6) xenografts. The
average time between inoculation/transplantation and randomization
was about 1 month (for SW872 and UZLX-STS3) or 2 months for
UZLX-STS5. Mice were bearing tumors on both sides, with an
average volume of ±300 mm3 and were grouped as follows: 1) control
mice treated with sterile water; 2) DOX treatment [1.2 mg/kg,
intraperitoneally (i.p.), twice per week] [18]; 3) PAZ treatment
[40 mg/kg,orally (p.o.) ], twice per day) [19]; 4) PAZ + DOX
combination (same doses and schedules as for single treatments). The
DOX schedule, with minimal toxicity, was used on the basis of the
Translational Oncology Vol. 7, No. 6, 2014 Pazopanib in Liposarcoma Xenografts Li et al. 667previous study [18]. Tumor volume was measured by digital caliper
three times a week. Relative tumor volume (%) was calculated by
comparing the tumor volumes of each group to those at the baseline
(day 0). The body weight of the mice as well as their well-being was
monitored daily. The treatment lasted 2 weeks, and afterward, mice
were sacrificed 2 hours after administration of the last treatment.
Tumor samples were immediately snap frozen in liquid nitrogen or
fixed in 4% buffered formalin solution for further analysis (for details
about the in vivo study design, see Table S1).
Western Blot Analysis
Tumor lysates were prepared from frozen samples and were used
for Western blot analysis as previously described [20]. A lysate of the
angiosarcoma cell line ASM with VEGFR2 activation was used as a
positive control. Chemiluminescence levels (Western Lighting from
PerkinElmer, Waltham, Massachusetts) were captured by the Fuji
Mini-LAS3000-Plus Imaging System (Fuji, Tokyo, Japan).
Histologic Assessment
Formalin-fixed paraffin-embedded tissue blocks were cut (4 μm)
for hematoxylin and eosin (H&E) and IHC stainings. Mitotic and
apoptotic activity and Ki67 index were assessed as previously
described [20]. Scoring of pHH3 and CC3 was performed to assess,
respectively, the proliferation and apoptosis of tumor cells by
counting positive nuclei or apoptotic bodies in 10 high power fields
(HPFs). All assessments were carried out under 400-fold magnifica-
tion (×400) with an LH-30M microscope (Olympus, Tokyo, Japan).
Microvascular density (MVD) was calculated as the average number
of CD34- or VEGFR2-positive vessels in the area of the highest
vascular density in five HPFs under 200-fold magnification (×200).
The total vascular area (TVA) of vessels was calculated as the average
area (μm2) of CD34-positive vessels in five HPFs under ×200 using
Cell D imaging software (Olympus), and images were captured with a
Color View digital camera (Olympus).U
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Figure 1. Representative images of H&E staining, MDM2 immunost
including H&E-stained images from the original patient samples. On
while the red cluster of signals (arrow) represents the amplified MDMStatistics
The comparisons between different groups for nonparametric
values (relative tumor volume, histologic assessment) were performed
using the Mann-Whitney U test. The value of P b .05 was considered
as statistically significant. STATISTICA software (StatSoft, version
12.0, Tulsa, Oklahoma) was used for all calculations.
Results
Characterization of Patient-Derived Models
UZLX-STS3 and UZLX-STS5 models were established from tumors
from patients diagnosed with DDLPS (Table S2). Tumors reached ±100
mm3 within 2 to 4 months in early passages (p.0 to p.3). Afterward, the
growth rates decreased and then remained stable (1-2 months). H&E
staining of subsequent xenograft passages from bothmodels confirmed the
presence of histologic features of the original tumors. MDM2
immunopositivity was observed in both models (Figure 1). MDM2
amplification was observed by FISH analysis in both UZLX-STS3 and
UZLX-STS5 (Figure 1) and was confirmed by qPCR (data not shown).
Tumor Volume Assessment
At the end of the 14-day treatment, the tumor volumes in the
control group increased nearly five times in UZLX-STS3, four times
in UZLX-STS5, and more than two times in SW872. Although
DOX treatment slightly delayed the tumor growth in UZLX-STS3
and UZLX-STS5, the difference in tumor volume compared to
untreated controls was significant only in the latter model (P b .005;
Table 1 and Figure 2).
In all models, at the end of the PAZ administration, the tumor
volumes were one to two times higher than those at the baseline.
Treatment with PAZ as a single agent significantly delayed the tumor
growth compared with control animals in all models (P b .005 in
SW872 and UZLX-STS3; P b .05 in UZLX-STS5) and DOX-treated
groups in UZLX-STS3 and SW872 (P b .005), although it did not
cause tumor shrinkage (Table 1 and Figure 2).IHC FISH
MDM2
aining, and FISH in UZLX-STS3 (p.7) and UZLX-STS5 (p.6) tumors,
FISH images, green signals identify chromosome 12 centromere,
2.
Table 1. Relative Tumor Volume Assessment in DDLPS Models after Treatment. Mean (%) ± SD
(%) was shown. Relative Tumor Volume Was Calculated by Comparing to the Tumor Volume at
the Baseline (Day 0)
Xenograft Model Control DOX PAZ PAZ + DOX
All models 379 ± 165 303 ± 114* 189 ± 80**## 153 ± 48**##
SW872 279 ± 65 271 ± 56 128 ± 22**## 125 ± 32**##
UZLX-STS3 479 ± 263 384 ± 175 177 ± 39**## 175 ± 54**##
UZLX-STS5 416 ± 55 274 ± 71** 270 ± 86* 157 ± 42**##$$
Statistical significance was calculated using Mann-Whitney U test.
Compared to control: *P b .05, **P b .005; compared to DOX: ##P b .005; compared to PAZ: $$P b .005.
668 Pazopanib in Liposarcoma Xenografts Li et al. Translational Oncology Vol. 7, No. 6, 2014The PAZ + DOX combination treatment inhibited tumor growth
compared to control animals and DOX-treated groups in all models
tested (P b .005). Only in the UZLX-STS5 the combination0
200
400
600
800
0 2 4 6 8 10 12 14
R
el
at
iv
e 
tu
m
o
r 
v
o
lu
m
e 
(%
) UZLX-STS3
Day
0
100
200
300
400
500
0 2 4 6 8 10 12 14
R
el
at
iv
e 
tu
m
o
r 
v
o
lu
m
e 
(%
)
UZLX-STS5
Control DOX PAZ PAZ+DOX
Day
0
100
200
300
400
0 2 4 6 8 10 12 14
R
el
at
iv
e 
tu
m
o
r 
v
o
lu
m
e 
(%
 
)
SW872
Day
Figure 2. Tumor volume evaluation in SW872, UZLX-STS3,
and UZLX-STS5 models. Tumor volume was measured three
times per week and is presented as a relative tumor volume (%)
compared to day 0. All data points are shown as mean ± SD of at
least six tumors per treatment group.treatment showed better tumor volume inhibition in comparison to
single PAZ treatment (P b .05; Table 1 and Figure 2).
Histologic Assessment
Regardless of the model, tumors in the control group showed
the highest level of mitotic activity among all treatment arms. PAZ
alone significantly reduced mitotic activity in all the models
in comparison with either control or DOX-treated cohorts, but
the reduction was most pronounced in SW872 and UZLX-STS3
(P b .005, compared to untreated tumors). The combination
of PAZ + DOX reduced antiproliferative activity by about two-
fold in all models (P b .05, compared to control and DOX
groups). These observations were confirmed by Ki67 and pHH3
immunostainings (Table 2).
In comparison with control, pro-apoptotic activity was observed in
PAZ-treated UZLX-STS3 and SW872 tumors (P b .05). PAZ +
DOX combination also induced a significant increase in apoptotic
activity in UZLX-STS3 and UZLX-STS5 (P b .05). The results of
apoptotic count assessment were confirmed by CC3 immunostaining
(Table 2). There was no superior effect observed on cell proliferation
or apoptosis in combination treatment group compared with
PAZ alone.
Assessment of Angiogenesis
The antiangiogenic effect of PAZ in xenografted liposarcomas was
evaluated by calculating MVD and TVA on the basis of CD34
and VEGFR2 immunostainings. As indicated by CD34 staining,
after 2-week treatment, the tumors in control or in DOX treatment
groups showed the highest vascular density in all models (Table 3 and
Figure 3). Both PAZ-based treatments significantly reduced MVD by
about two-fold and TVA by nearly three-fold in PAZ and PAZ +Table 2. Histologic Assessment of Proliferative and Apoptotic Activity of Tumor Cells. Histologic
Assessment Was Performed for the Tumors Collected at the End of the Treatment. Results Are
Shown as Fold Changes of Mean for Each Group in Comparison with Control. Arrows Indicate an
Increase (Arrow Up) or Decrease (Arrow Down) of Proliferative or Apoptotic Activity in Treated
Tumors versus Respective Controls
All Models SW872 UZLX-STS3 UZLX-STS5
Proliferative activity
H&E
DOX ↓1.3* ↓1.3* ↓1.7* 1.0
PAZ ↓2.2**## ↓2.1**## ↓2.5**# ↓1.7*#
PAZ + DOX ↓2.0**## ↓1.8**## ↓2.3**# ↓2.4*##
pHH3
DOX ↓1.2 ↑1.1 ↓1.5* ↓1.2*
PAZ ↓1.9**# ↓2.0**## ↓1.8* ↓1.6*
PAZ + DOX ↓1.9*# ↓2.0**## ↓1.9* ↓1.2
Ki67
DOX 1.0 1.0 ↑1.2 1.0
PAZ ↓1.2*# ↓1.2* ↓1.2# ↓1.2
PAZ + DOX ↓1.5**## ↓1.3**# ↓2.7**## 1.0
Apoptotic activity
H&E
DOX ↑1.1 1.0 ↑1.7* 1.0
PAZ ↑1.4 ↑1.4* ↑2.2** 1.0
PAZ + DOX ↑1.6* ↑1.3 ↑2.2** ↑3.0*
CC3
DOX ↑1.1 1.0 ↑1.3 ↑2.0
PAZ ↑1.3 ↑1.1 ↑1.7** 1.0
PAZ + DOX ↑1.3 1.0 ↑1.6** ↑4.0*
Statistical significance was calculated using Mann-Whitney U test.
Compared to control: *P b .05, **P b .005; compared to DOX: #P b .05, ##P b .005.
H&E, hematoxylin and eosin staining; pHH3, phospho-histone H3 immunostaining; CC3, cleaved caspase-
3 immunostaining.
Table 3. Assessment of MVD and TVA. Assessment Was Done for the Tumors after Treatment.
Results Are Shown as Fold Changes of Mean for Each Group in Comparison with Control. Arrows
Indicate an Increase (Arrow Up) or Decrease (Arrow Down) of MVD or TVA in Treated Tumors
versus Respective Controls
All Models SW872 UZLX-STS3 UZLX-STS5
MVD
CD34
DOX 1.0 ↑1.3* ↓1.1 ↓1.2
PAZ ↓2.3**## ↓2.0**## ↓2.4**## ↓3.3*#
PAZ + DOX ↓2.3**## ↓2.0**## ↓2.4**## ↓3.3*#
VEGFR2
DOX 1.0 1.0 1.0 ↓1.2
PAZ ↓2.0 **## ↓2.0**## ↓2.2**## ↓2.0*#
PAZ + DOX ↓2.0 **## ↓2.0**## ↓2.2**## ↓2.0**##
TVA
CD34
DOX ↓1.2 ↑1.3 ↓1.7 ↓1.9
PAZ ↓2.6**## ↓1.7*# ↓3.4*# ↓4.2*#
PAZ + DOX ↓2.9**## ↓1.7*## ↓3.9**## ↓4.7*#
Statistical significance was calculated using Mann-Whitney U test.
Compared to control: *P b .05, **P b .005; compared to DOX: #P b .05, ##P b .005.
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tumors (P b .05; Table 3 and Figure 3). In addition, results of
VEGFR2 immunostaining confirmed results obtained with CD34
staining (Table 3).
Evaluation of Oncogenic Signaling Pathways
Western blot analysis showed that AKT and MAPK were activated
in all models tested, but substantial expression of VEGFR2 was only
detected in SW872. No evident inhibition in either AKT or MAPK
signaling pathways was observed in the treatment groups in any of the
models tested (Figure S1).
Discussion
The present in vivo study reports two new patient-derived DDLPS
xenografts UZLX-STS3 and UZLX-STS5 and their use for in vivoControl DOX
UZLX-STS3
UZLX-STS5
SW872
Figure 3. Representative images of tumor vascularity using CD34
Images were captured under 400-fold magnification.testing of antiangiogenic and cytotoxic compounds. Both established
DDLPS xenograft models retained histologic and molecular features
of the respective original tumor. Interestingly, it was noticed that their
growth rate increased after several passages without affecting
the tumors' histopathologic features. This phenomenon has been
described before in a study using myxoid liposarcoma xenografts [21].
Recent studies revealed that genetic alternations associated with
stromal microenvironment occurred during passages of xenografts
[22,23]. Therefore, it was hypothesized by some researchers that
acquired growth advantage due to genetic alternations correlated to
mouse stromal compartment during engraftment may contribute to
the change in the growth rate of the xenograft [24].
We have previously shown that patient-derived xenografts from
gastrointestinal stromal tumors can be successfully used for in vivo
preclinical drug testing [20,25]. In the current study, we present the
activity of PAZ alone and in combination with DOX in patient- and
cell line–derived DDLPS xenografts.
In the present study, DOX did not display significant antitumor
activity in the three DDLPS models when compared with the control
groups. Such result was not unexpected, since DOX usually only has
very limited cytotoxic effects in DDLPS in the clinic. The lack of
response may have also been due to the relatively low dose and i.p.
administration of DOX as used in our experiments (1.2 mg/kg i.p.,
twice per week). We used this schedule based on published in vivo
experience of other groups with this well-tolerated scheme [18,26,27] to
minimize the potential toxicity of PAZ + DOX combination in mice.
PAZ delayed tumor growth, although there was no tumor
shrinkage observed in any model. In the clinic, the primary goal of
palliative treatment of locally advanced or metastatic STS is to
prolong time to progression [28]. Accordingly, the objective response
rate to experimental treatments in STS is not used as a primary
endpoint of early clinical trials in this setting anymore [29]. Of note,
the pivotal registration trial of PAZ in non-adipocytic sarcomas also
showed that the rate of objective responses (all partial responses)PAZ PAZ+DOX
immunostaining in SW872, UZLX-STS3, and UZLX-STS5 models.
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[12]. Tumor growth delay rather than tumor shrinkage was also
observed in synovial sarcoma and rhabdomyosarcoma models treated
with PAZ [30,31]. Therefore, a delayed tumor growth in our PAZ-treated
tumors during the period of treatment implies a promising effect of this
drug, which is currently not used for the treatment of liposarcomas
outside of clinical trials.
Furthermore, emerging evidence indicates that PAZ does not only
inhibit VEGF-induced endothelial cell proliferation in vitro but also
blocks angiogenesis in vivo and in patients with STS [19,32,33]. In the
present study, a remarkable reduction inMVDandTVAwas observed in
animals exposed to PAZor PAZ-based combination treatment, regardless
of the models tested. These changes suggested that PAZ treatment had
significant antiangiogenic effect and decreased the blood flow to/in the
tumor. Nevertheless, we did not observe any synergistic effect between
PAZ and the anthracycline chemotherapeutic agent used in our
experiments. The reason for the lack of synergy may be the disturbance
of the balance between antiangiogenesis and vascular normalization as
hypothesized by some researchers [34]. Such compounds can initially
normalize the tumor vasculature, but continuous aggressive antiangio-
genic therapy may eventually remove these vessels. Consequently, the
vascular environment of tumor can become resistant to subsequent
treatments and the use of the antiangiogenic compounds may even limit
the delivery of other cytotoxic drugs; however, this hypothesis should be
tested in the experimental setting.
To investigate whether PAZ exhibited a direct effect on oncogenic
signaling pathways of tumor cells, Western blot analysis was
conducted. VEGFR2 was hardly detected by Western blot analysis
in the samples obtained from UZLX-STS3 and UZLX-STS5 in
contrast to SW872, in which cells also showed VEGFR2 expression
in vitro (data not shown). As only a fragment of tumor samples
instead of whole tumors was used for lysing, it was expected that
majority of proteins detected in the sample were from tumor cells and
not from vessels. This may partially explain why VEGFR2 expression
was remarkably higher in SW872 than those in UZLX-STS3 and
UZLX-STS5, in which VEGFR2 may mostly originate from vessels
rather than from tumor cells. However, AKT and MAPK pathways
were both activated in the tumors of all the models, suggesting that
VEGFR2may not be primarily responsible for the activation of AKT
and MAPK pathways in the DDLPS models. It has been shown that
the activation of AKT is involved in the oncogenesis of DDLPS and
ALT [35] and the activation of the AKT pathway in synovial cell lines
can be inhibited by PAZ [30]. However, in our study, the inhibitory
effect of PAZ on either AKT or MAPK pathway was not evident,
suggesting that PAZmay not have a direct effect on oncogenic signaling
pathways of tumor cells in the DDLPS xenografts. Taken all above
together, we hypothesized that the antitumor activity of PAZ in
DDLPS was mainly a result of antiangiogenic effect on tumor vessels
rather than inhibition in cell signaling pathways of tumor cells.
Moreover, we observed a significant suppression of cell prolifer-
ation in PAZ-treated tumors. PAZ as a single agent or combined with
DOX, however, did not enhance the pro-apoptotic activity in
comparison with DOX. However, data from previous studies
concerning whether PAZ had direct proliferative-inhibitory efficacy
on STS cells in vitro were controversial. In synovial sarcoma cells,
PAZ inhibited cell proliferation in vitro through inducing G1 arrest
[30]. However, PAZ did not cause any effect on cell viability in vitro
in rhabdomyosarcoma and bone sarcoma cell lines, although tumor
growth delay and inhibition of angiogenesis were observed in vivo[31]. In the study of synovial sarcoma cell lines, activation of PDGFR
and AKT pathways was also suppressed in the synovial cell lines with
high level of PDGFR expression, implying that molecular factors of
cell signaling may have an impact on the response of tumor cells to
PAZ. Given these evidences above, it was rational to deduce that the
direct effect of PAZ on tumor cells depended on the status of
dominant tyrosine kinases of signaling pathways in tumor cells.
However, as we discussed above, the evident inhibition in both AKT
and MAPK pathways was not observed in the present study, which
suggested that PAZ may not have a direct effect on oncogenic
signaling pathways of tumor cells in the DDLPS models. However,
since cancer cell survival and proliferation relies on neovascular
vessels to supply oxygen and nutrients, angiogenesis blockade can
also lead to inhibition of cell proliferation [36]. Thus, we
hypothesized that proliferation arrest of tumor cells was mainly
caused by angiogenesis inhibition in the PAZ-treated tumors in our
DDLPS models.
It was already reported that DDLPS xenograft models exhibit a
variable response to targeted therapies [37], which was also noticed
in our study. Single agent PAZ treatment did not cause a
significant difference in tumor volume compared with DOX
treatment in UZLX-STS5 as it did in SW872 and UZLX-STS3, but
combination treatment showed better efficacy than either single PAZ or
DOX treatment in UZLX-STS5. Considering DDLPS as a highly
heterogeneous tumor type, such distinct response was not unexpected,
as observed also in a clinical setting. The difference in response may be
due to the diverse histology of the DDLPS tumors.
In the phase II study with PAZ in multiple subtypes of STS,
which was based on a two-stage design, the liposarcoma stratum was
closed after stage 1 because the stratum did not meet the predefined
level of antitumor activity [14]. Patient entry into this trial and the
go/no go decision to proceed to stage 2 was based on the local
histopathologic diagnosis. All diagnoses were reviewed by inde-
pendent pathologists while the trial was proceeding. On the basis of
this review, a number of treated cases were revised, some patients
entered into non-liposarcoma stratum of the trial were reclassified
as having DDLPS, and they did benefit from PAZ treatment
[11,14]. The fact that liposarcomas were excluded from the
consecutive phase III trial is thus to be regarded as a methodological
artifact. Hence, two phase II trials are currently readdressing this issue
(ClinicalTrials.gov identifier: NCT01692496 and NCT01506596). In
the present preclinical study, we clearly demonstrated the antitumor
potential of PAZ in liposarcoma models, and we were able to show that
the antitumor efficacy was mainly due to antiangiogenic effects of PAZ.
We strongly believe that PAZ deserves prospective clinical testing in
patients with adipocytic tumors.
In conclusion, our newly established DDLPS xenograft models,
which recapitulate the histologic andmolecular features ofDDLPS in the
clinic, provide a very useful platform for investigation of the efficacy of
novel therapies inDDLPS.More importantly, we show for the first time
that PAZ has antitumor activity in DDLPS xenografts, mainly through
angiogenesis inhibition. Our results provide supportive evidence for the
exploration of single agent PAZ in clinical trials of patients withDDLPS.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.09.007.
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